Market Overview

Why ChemoCentryx's Stock Is Trading Lower Today


ChemoCentryx (NASDAQ: CCXI) shares are trading lower on Thursday after the company announced topline data from its Phase II AURORA clinical trial of Avacopan in the treatment of Hidradenitis Suppurativa.

ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. 

ChemoCentryx shares were trading down 6.90% at $48.64 on Thursday. The stock has a 52-week high of $65.43 and a 52-week low of $7.88.


Related Articles (CCXI)

View Comments and Join the Discussion!

Posted-In: why it's movingNews